Vindhya Vijay
Overview
Explore the profile of Vindhya Vijay including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
138
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gritti I, Wan J, Weeresekara V, Vaz J, Tarantino G, Bryde T, et al.
Cancer Discov
. 2024 Sep;
15(2):382-400.
PMID: 39326063
This work combines functional studies in model systems and examination of human tumor specimens to define a central oncogenic pathway driven by DNAJB1-PRKACA fusions in FLC. DNAJB1-PRKACA-mediated inactivation of the...
2.
Vijay V, Karisani N, Shi L, Hung Y, Vu P, Kattel P, et al.
bioRxiv
. 2024 Jul;
PMID: 39026794
Biliary tract cancers (BTCs) are a group of deadly malignancies encompassing intrahepatic and extrahepatic cholangiocarcinoma, gallbladder carcinoma, and ampullary carcinoma. Here, we present the integrative analysis of 63 BTC cell...
3.
Wu M, Kondo H, Kammula A, Shi L, Xiao Y, Dhiab S, et al.
Science
. 2024 Jul;
385(6705):eadl6173.
PMID: 38991060
() is the most commonly mutated metabolic gene across human cancers. Mutant IDH1 (mIDH1) generates the oncometabolite (R)-2-hydroxyglutarate, disrupting enzymes involved in epigenetics and other processes. A hallmark of -mutant...
4.
Weiss-Sadan T, Ge M, Hayashi M, Gohar M, Yao C, de Groot A, et al.
Cell Metab
. 2023 Apr;
35(4):722.
PMID: 37019082
No abstract available.
5.
Shi L, Shen W, Davis M, Kong K, Vu P, Saha S, et al.
Nat Cancer
. 2023 Mar;
4(3):365-381.
PMID: 36914816
Adult liver malignancies, including intrahepatic cholangiocarcinoma and hepatocellular carcinoma, are the second leading cause of cancer-related deaths worldwide. Most individuals are treated with either combination chemotherapy or immunotherapy, respectively, without...
6.
Weiss-Sadan T, Ge M, Hayashi M, Gohar M, Yao C, de Groot A, et al.
Cell Metab
. 2023 Feb;
35(3):487-503.e7.
PMID: 36841242
Multiple cancers regulate oxidative stress by activating the transcription factor NRF2 through mutation of its negative regulator, KEAP1. NRF2 has been studied extensively in KEAP1-mutant cancers; however, the role of...
7.
Wu M, Shi L, Dubrot J, Merritt J, Vijay V, Wei T, et al.
Cancer Discov
. 2021 Dec;
12(3):812-835.
PMID: 34848557
Significance: Mutant IDH1 inhibition stimulates cytotoxic T-cell function and derepression of the DNA demethylating enzyme TET2, which is required for tumor cells to respond to IFNγ. The discovery of mechanisms...
8.
Vijay V, Miller R, Vue G, Pezeshkian M, Maywood M, Ast A, et al.
Leuk Res
. 2019 Jul;
84:106180.
PMID: 31299413
One of the greatest challenges in treating acute myeloid leukemia (AML) is chemotherapy refractory disease. Previously, we demonstrated a novel mechanism whereby AML-induced endothelial cell (EC) activation leads to subsequent...
9.
Drusbosky L, Singh N, Hawkins K, Salan C, Turcotte M, Wise E, et al.
Blood Adv
. 2019 Jun;
3(12):1837-1847.
PMID: 31208955
Patients with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) are generally older and have more comorbidities. Therefore, identifying personalized treatment options for each patient early and accurately is essential....
10.
Butterworth E, Dickerson W, Vijay V, Weitzel K, Cooper J, Atkinson E, et al.
J Vis Exp
. 2018 Feb;
(131).
PMID: 29443037
Using traditional histological methods, researchers are hampered in their ability to image whole tissues or organs in large-scale 3D. Histological sections are generally limited to <20 µm as formalin fixed...